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Abstract 
Mannose-capped lipoarabinomannan (ManLAM) is considered an important virulence 
factor of Mycobacterium tuberculosis. However, while mannose caps have been reported to be 
responsible for various immunosuppressive activities of ManLAM observed in vitro, there is 
conflicting evidence about their contribution to mycobacterial virulence in vivo. Therefore, we 
used M. bovis BCG and M. tuberculosis mutants that lack the mannose cap of LAM to assess 
the role of ManLAM in the interaction of mycobacteria with the host cells, to evaluate vaccine-
induced protection and to determine its importance in M. tuberculosis virulence. Deletion of the 
mannose cap did not affect BCG survival and replication in macrophages, although the capless 
mutant induced a somewhat higher production of TNF. In dendritic cells, the capless mutant 
was able to induce the up-regulation of co-stimulatory molecules and the only difference we 
detected was the secretion of slightly higher amounts of IL-10 as compared to the wild type 
strain. In mice, capless BCG survived equally well and induced an immune response similar to 
the parental strain. Furthermore, the efficacy of vaccination against a M. tuberculosis challenge 
in low-dose aerosol infection models in mice and guinea pigs was not affected by the absence 
of the mannose caps in the BCG. Finally, the lack of the mannose cap in M. tuberculosis did 
not affect its virulence in mice nor its interaction with macrophages in vitro. Thus, these results 
do not support a major role for the mannose caps of LAM in determining mycobacterial 
virulence and immunogenicity in vivo in experimental animal models of infection, possibly due 
to redundancy of function. 
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Introduction 
The cell envelope of M. tuberculosis is considered a major determinant of virulence in 
this global pathogen. A major component of the cell envelope of all mycobacteria is 
lipoarabinomannan (LAM) (Briken et al., 2004; Chatterjee et al., 1998; Gilleron et al., 2008; 
Nigou, 2003), which appears to play a key role in the interaction with the host, and modulation 
by the bacterium of the host response (Briken et al., 2004; Gilleron et al., 2008; Mishra et al., 
2011; Nigou et al., 2002; Nigou et al., 2003). This complex molecule of approximately 17 kDa 
is the largest member of a series of lipoglycans of varying size based on a conserved mannosyl-
phosphatidyl-myo-inositol anchor. In slow growing mycobacteria, such as M. tuberculosis, the 
presence of one to three mannopyranosyl residues linked to the non-reducing ends of the 
arabinan domain constitute the mannose cap of LAM (ManLAM), while in fast-growing 
mycobacteria, such as Mycobacterium smegmatis, this latter domain is capped with phospho-
inositol residues (PILAM) (Nigou, 2003) and in some species like M. chelonae, no such 
capping motif is present (Guerardel et al., 2002). The proportion of LAM non-reducing termini 
that are capped with mannose varies among different species of slow-growing mycobacteria 
and among strains of M. tuberculosis, with fully virulent M. tuberculosis laboratory strains 
having up to 70% capping (Chatterjee et al. 1992, Khoo et al., 1995). The number of mannose 
residues per cap is also variable even within LAM from the same species or strain (Nigou, 
2003). 
A large number of studies have assigned a role in virulence to LAM. Initial studies 
aiming at determining the role of LAM in mycobacterial virulence addressed the in vitro effects 
of the purified molecules. These studies showed that LAM from M. tuberculosis is able to alter 
macrophage functions associated with protective immunity (Chan et al., 1991; Fratti et al., A
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2003; Kang et al., 2005; Pathak et al., 2005; Sibley et al., 1988). It was additionally shown that 
LAM from mycobacteria of different virulences have different immuno-modulatory activities 
(Adams et al., 1993; Bradbury et al., 1993; Chatterjee et al., 1992; Knutson et al., 1998; Roach 
et al., 1993; Vergne et al., 2003; Yoshida et al., 1997). Numerous studies have so far suggested 
a role of ManLAM in binding to and in modulating the function of macrophages and dendritic 
cells (Chan et al., 1991; Fratti et al., 2003; Geijtenbeek et al., 2003, Kang et al., 2005; Maeda 
et al., 2003; Nigou et al., 2001; Schlesinger, 1993; Schlesinger et al., 1994; Sibley et al., 1988; 
Tailleux et al., 2003; Torrelles et al., 2006; Vergne et al., 2003; Welin et al., 2008).  
The studies above have led to the conclusion that ManLAM is an important virulence 
factor in tuberculosis, and that mannose capping plays an essential role. However, 
interpretation of these experiments is complex, with the experiments comparing ManLAM 
from fully virulent M. tuberculosis either with ManLAM from strains with a lower proportion 
of mannose capping, or with PILAM (Khoo et al., 1995). It is therefore important to carry out 
experiments directly comparing LAM produced by isogenic strains differing only in their 
terminal mannosyl decoration. 
Enzymatic removal of mannose residues with α-mannosidase revealed that the inhibition 
of IL-12 secretion by human dendritic cells caused by BCG ManLAM is strictly dependent on 
an intact molecule (Nigou et al., 2001). However, to unambiguously study the role of mannose 
capping of LAM in an infectious setting, we have been using genetically engineered mutants in 
which the cap is not added. A mannosyltransferase encoded by the M. tuberculosis capA gene 
(rv1635c) is responsible for the addition of the first mannose residue of the mannose cap in an 
α(1→5) linkage (Dinadayala et al., 2006). Previously, we identified homologous enzymes in 
M. marinum and M. bovis BCG (Appelmelk et al., 2008). Disruption of the capA gene resulted A
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in bacteria deficient in the biosynthesis of the mannose cap of LAM (Appelmelk et al., 2008; 
Dinadayala et al., 2006). 
When we tested capless mutants of M. marinum and M. bovis BCG in vitro and in vivo 
(Appelmelk et al., 2008), we obtained the surprising result that there was no evidence for an 
altered host-pathogen interaction, and that capless M. marinum and BCG mutants were not less 
virulent than their respective parent strains. Thus, the data obtained with live isogenic strains 
were discrepant with the mass of data obtained earlier with purified ManLAM.  
Here we follow up on our previous study of the role of the mannose cap further using 
isogenic strains differing only at the capA locus: we (1) look at the role of the mannose cap in 
the protective efficacy of BCG in vaccination studies, and (2) extend our studies on virulence 
to look at M. tuberculosis itself.   
M. bovis BCG, the vaccine for tuberculosis protects well against disseminated TB, 
including meningitis in childhood, but protection against adult pulmonary TB is highly 
variable, ranging from 80% to no protection at all (reviewed by Colditz et al., 1994), and a 
more effective vaccine is therefore required. As ManLAM has been reported as blocking 
phagolysosome fusion, and/or inducing IL-10, and LAM lacking mannose caps does not 
exhibit these activities, we hypothesized both that a capless mycobacterium would induce a 
different type of immune response, being less immunosuppressive and thus more protective. 
We have therefore tested a capless BCG as a vaccine both in a low-dose challenge model in 
mice, in contrast to the high-dose challenge model used by Festjens et al. (2011) and in the 
guinea pig model. 
A
cc
ep
te
d 
A
rti
cl
e
© 2012 Blackwell 1 Publishing Ltd 
To date, in vivo virulence studies have been carried out with capless mutants of BCG and 
M. marinum, but not M. tuberculosis itself.  Here we test the virulence of capless M. 
tuberculosis in a low dose aerosol model. 
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Results: 
 We first studied a capless mutant of BCG. This strain has already been used in an 
earlier publication where it was fully characterized and shown to synthesize LAM devoid of 
mannose caps (see supplementary figure 4 from Appelmelk et al., 2008). Here we extended 
the analysis of its interaction with the host cells initially in in vitro assays using cultured 
macrophages and dendritic cells and subsequently in in vivo experiments. 
 
Response of mouse macrophages to wild type BCG and capless BCG mutant. 
Macrophages are in the first line of cellular defense against mycobacterial infection. 
However, as intracellular pathogens, mycobacteria have evolved strategies to manipulate the 
host cell mechanisms responsible for their killing. ManLAM inhibits the maturation of 
phagosomes (Fratti et al., 2003; Vergne et al., 2003) and prevents macrophage activation by 
IFNγ (Chan et al., 1991; Sibley et al., 1988). To assess the importance of the mannose caps in 
BCG survival and macrophage activation, we infected bone marrow-derived macrophages 
(BMDM) from Balb/c mice with either the parental BCG strain or the capless mutant strain 
and measured mycobacterial growth and the production of TNF and reactive nitrogen species 
by the macrophages. No differences in phagocytosis were observed between the mutant and 
parental BCG, with both BCG strains being internalized to the same extent following 
exposure of the macrophage monolayers to similar multiplicity of infection (MOI=2) leading 
to similar CFU counts at time 0 of infection, i.e. after 4 hours of contact of the macrophages 
with the inocula (Fig 1A).  Both strains replicated in macrophages with similar growth rates 
(Fig 1A). Activation of the macrophages with IFNγ or IFNγ plus TNF caused macrophages to 
kill BCG but again both BCG strains behaved in the same manner (Fig 1B). Despite the same A
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degree of replication in resting macrophages and the similar bacterial loads found at the end 
of the experiment, the mutant induced higher amounts of TNF secretion at day 7 of infection 
(Fig 1C). The production of reactive nitrogen species was also assessed, with both BCG 
strains inducing the same amount (Fig 1D). These data show that the lack of mannose caps in 
LAM leads to different signaling in infected macrophages but has no consequences on the 
ability of BCG to proliferate or survive intracellularly. 
 
Response of mouse dendritic cells to wild type BCG and capless BCG mutant  
Dendritic cells (DCs) are key players in the induction of cellular immune responses 
against mycobacteria (Murray, 1999). It has been shown that ManLAM (but not non-capped 
LAM) prevents human DC maturation, inhibits the production of the pro-inflammatory 
cytokines IL-12 and TNF (Nigou et al., 2001; Nigou et al., 2002) and triggers the production 
of the immunosuppressive cytokine IL-10 in lipopolysaccharide (LPS)-activated DCs 
(Geijtenbeek et al., 2003). To evaluate the effect of the mannose capping of LAM in the 
activation and modulation of DC function, we infected bone marrow-derived dendritic cells 
(BMDC) from Balb/c mice with the parental BCG or the mutant strain and measured the 
induction of co-stimulatory molecules and the production of cytokines released into the 
culture supernatants. Both wild type and mutant BCG activated DC and induced the same 
extent of up-regulation of co-stimulatory molecules (MHC-II, CD40 and CD86) (Fig. 2A). 
They also induced the secretion of the same amount of IL12p70 and TNF but, interestingly, 
the mutant strain induced higher amounts of IL-10 (Fig. 2B). Thus both in macrophages and 
DC, mannose capping of LAM affects cytokine induction.  
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Capless BCG mutant replicates and induces identical immune responses in vivo as 
compared to the wild type strain. 
As described above, ManLAM is proposed to be a key molecule in mycobacterial 
virulence (reviewed by Nigou, 2003; Briken et al., 2004) and the mannose capping of LAM 
may be related to an immunosuppressive activity of this lipoglycan impacting on vaccine 
efficacy of BCG. We therefore wished to determine the protective efficacy of the capless 
BCG strain.   
Before testing the protective abilities of the parent BCG and its capless mutant we 
compared their replication in vivo, and the immune response they induced.  In order to 
compare the growth of wild type and capless BCG, Balb/c mice were intravenously infected 
with 5x104 CFU of either the parental strain or the capless mutant and groups of five mice 
were sacrificed at days 1, 10, 20, 30 and 60 post-infection. No differences in mycobacterial 
loads were observed for the two strains in either the spleen or the liver (Fig.3A). In the 
spleen, both BCG strains proliferated until around day 20, with mice reducing the bacterial 
load afterwards, while in the liver, the growth of the parent and mutant strains was slowly 
controlled after day 10, with bacterial numbers decreasing over time, as has been classically 
described (Gheorghiou et al., 1985).  
We next took spleen cells from infected mice, and stimulated them in vitro with BCG 
antigens to assess cytokine responses. Cells from capless mutant-infected animals released 
the same amount of IFNγ, TNF and IL-10 as cells from mice infected with the wild type 
strain (Fig 3B). No differences were found in the number of several different immune cell 
populations (table 1). A
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These data do not substantiate our hypothesis that a capless BCG would induce a 
different type of immune response. 
 
Wild type and capless BCG induce the same level of protection against a M. 
tuberculosis challenge in a murine low dose aerosol infection model.  
We proceeded to carry out a protection study comparing BCG and its capless mutant.  
Festjens et al. (2011) used a high dose (5x104 CFU intravenous or 2x105 CFU intratracheal) 
virulent M. tuberculosis challenge to assess the protection afforded by wild type or capless 
BCG. We reasoned that this high dose might overwhelm host immunity and hence mask 
protective efficacy, and therefore used a low dose exposure aerosol challenge with virulent 
M. tuberculosis to compare the protection afforded by either wild type BCG or its capless 
mutant.  
Balb/c mice were intra-dermally inoculated with 5x104 CFU of the parental or the 
mutant strain and the dissemination of BCG to the lung and spleen was determined 70 days 
post-vaccination. Very low numbers of bacteria were detected in the spleen and no CFUs 
could be detected in the lung of both vaccinated groups (Fig 4A), indicating a poor 
dissemination of BCG after intradermal inoculation. We then determined if a specific 
immune response could be observed in the lung of these vaccinated mice. Seventy days post-
vaccination, leukocytes isolated from the lungs of both immunized groups produced the same 
amounts of the protective cytokines IFNγ, TNF and IL-17 after in vitro re-stimulation with 
BCG antigens (Fig 4B). Furthermore, both BCG strains induced the same number of 
CD4+IFNγ+ producing cells (Fig 4C), showing that both the parental strain and the capless A
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mutant induce a similar type of immune response in the lung.  No differences in cytokine 
production by spleen cells from either group were detected (data not shown).  
Seventy days post-vaccination, the two groups of immunized mice and a control group 
of non-immune animals were subjected to a low dose aerosol challenge with a virulent strain 
M. tuberculosis (strain H37Rv) leading to the implantation of <100 CFU in the lung. The 
lungs and spleens were harvested at different time points and the numbers of CFU were 
determined. As expected, 30 days after the challenge with M. tuberculosis, a significantly 
reduced bacterial growth was observed in the lungs and spleens of vaccinated mice when 
compared to unvaccinated controls (Fig 4D, p<0.001). The capless mutant induced the same 
level of protection as the wild type strain.  
 
Wild type and capless BCG induce the same level of protection against a M. 
tuberculosis challenge in a low dose guinea pig aerosol model.  
Guinea pigs are a key TB vaccine model, as they present pathological features 
resembling the human disease and, like humans, express CD1b an antigen presenting 
molecule which is not expressed by mice and that is known to present LAM to antigen-
specific T cells (Prigozy et al., 1997; Sieling et al., 1995). Thus, potential LAM-mediated 
immunity may not be evident in mice, making tests in the guinea pig model prone to show 
differences in protection not seen in mice. We thus tested capless vs. WT BCG in a low dose 
aerosol challenge (10-50 CFU in the lung upon infection) in the guinea pig model. Figure 5 
shows that the capless BCG is not more protective as a capped BCG.  
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Isolation  of a capless M. tuberculosis mutant.  
The results obtained here as well as the already published information (Appelmelk et 
al., 2008; Festjens et al., 2011) point to a redundancy of the mannose cap in BCG and M. 
marinum virulence. However, BCG and M. tuberculosis differ drastically in terms of 
virulence and one could argue that the mannose cap in M. tuberculosis may have a more 
essential role for its virulence than in BCG. We thus studied a M. tuberculosis mutant lacking 
the ability to synthesize the mannose cap to evaluate the role of mannose-capped LAM in M. 
tuberculosis virulence. A capless mutant of M. tuberculosis H37Rv was constructed using the 
pGOAL-pNIL procedure (Parish et al., 2000) exactly as described for M. bovis BCG, 
including isolation of the complementant (Appelmelk et al, 2008). Supplementary Figure 1 
provides genetic evidence that indeed Rv1635c was disrupted in the mutant and that in the 
complementant we succeeded in the reintroduction of an intact copy of this gene.  
Mild acid hydrolysis of purified LAM followed by analysis of liberated 
oligosaccharides by capillary electrophoresis (Nigou et al., 2000) provided evidence that all 
cap motifs were missing (see Supplementary Figure 2). We investigated if differences in 
glycosylation, other than the absence of the cap, were present in the knockout by two 
independent approaches, i.e. SDS-PAGE followed by immunoblotting with glycosylation-
specific probes (Supplementary Figure 3) and, secondly, mass spectrometric analysis of 
isolated PIMs (Supplementary Figure 4). No evidence for differences in glycosylation other 
than in the cap was found.  
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Wild type and capless M. tuberculosis show similar survival in murine 
macrophages and induce similar amounts of TNF and NO in vitro.  
We tested the interaction of wild type and capless M. tuberculosis with Balb/c 
macrophages. As shown in Figure 6A the phagocytosis and growth rate of the two strains in 
resting BMDM was similar. The restriction of their growth in macrophages following 
activation by cytokines was also of the same extent (Figure 6B). The induction of TNF 
secretion and nitrite production did not differ significantly between the two strains (Figure 
6C and D). Hence, the difference in TNF production observed in capless BCG (see Figure 1 
C) was not found for capless M. tuberculosis.  
Wild type and capless M. tuberculosis behave similarly in vivo with regards to 
replication and cytokine induction. 
The M. tuberculosis wild type strain, capless mutant, as well as a complemented strain 
were then used for in vivo infection studies. Balb/c mice were infected by the low-dose 
aerosol route. Infection resulted in the implantation of 10 to 25 bacilli in the lungs of each 
animal. Mice were sacrificed at days 1, 60 and 120 post-infection and the bacterial loads in 
the lung and spleen determined. The course of the infection is presented in Figure 7A and 
shows that all strains replicated to similar extents in both organs, with mice stabilizing the 
infection after day 60 post-infection in both the lung and the spleen at similar bacterial loads. 
In addition, an identical immune response was observed for all the strains, with the 
production of similar amounts of IFNγ, TNF and IL-17 by spleen cells of mice with 60 days 
of infection (Fig. 7B). No IL-10 was detected in culture supernatants (data not shown). We 
extended this study to the widely used C57/BL6 mouse strain. Mice were infected as 
previously described and sacrificed at days 1 and 120 post-infection. Results are expressed as A
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"log CFU increase" corresponding to the difference of growth, in log CFU between day 1 and 
day 120. Like in the Balb/c mouse model, there were no significant differences in growth 
between the parental and the capless strain (Fig. 7C). 
 
Discussion: 
The cell envelope of M. tuberculosis plays an important role in the pathogenesis of 
tuberculosis. For years, the mannose-capped lipoarabinomannan (ManLAM) has been 
considered a key factor in host cell recognition and immunomodulation. The present work 
questions the importance of mannose capping of LAM as a requirement for virulence by 
showing that the in vivo growth in mice of mycobacteria (M. bovis BCG and M. tuberculosis) 
that are deficient in the biosynthesis of the mannose cap is not affected, and that a BCG 
mutant lacking mannose caps is as effective as a vaccine as its capped parent strain in low-
dose (<100 CFU) aerosol models in mice and guinea pigs. These data are surprising since 
mannose capping of LAM is found in slow growing mycobacteria, amongst which are many 
pathogenic species, but is (almost completely) lacking in fast growing, environmental non-
pathogenic species. 
It has been shown in vitro that, at the level of the macrophage, purified ManLAM 
interferes with phagosome maturation (Fratti et al., 2003; Vergne et al., 2003) and IFNγ-
dependent activation (Chan et al., 1991; Sibley et al., 1988). ManLAM inhibits IL-12 
secretion by LPS-stimulated human dendritic cells (Nigou et al., 2001). In addition, 
ManLAM also prevents DC activation as measured by CD80, CD83 and CD86 expression 
and triggers secretion of IL-10 by LPS primed human DCs through DC-SIGN binding 
(Geijtenbeek et al., 2003). Together these data demonstrate an immunosuppressive activity of A
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this lipoglycan and suggest that a capless Mycobacterium would be attenuated and would 
replicate less well in macrophages. Importantly, these studies were all done with purified 
ManLAM, not live bacteria. 
Our in vitro findings comparing BCG with isogenic capless BCG showed that mannose 
capping of LAM is not crucial for mycobacteria survival in macrophages (Fig. 1A,B), with 
the capless BCG mutant growing exactly as the wild type strain both in non-activated and in 
activated bone marrow-derived primary murine macrophages (Fig. 1B) Our data are in 
agreement with two other studies where capless BCG replicated as well as its parent in either 
human THP-1 macrophages (Appelmelk et al., 2008) or in the murine macrophage cell line 
Mf4/4 (Festjens et al., 2011). Hence, the prediction that the mannose cap of LAM would 
influence mycobacterial survival does not come true in mice. With regard to cytokine 
induction in vitro, no difference was seen for IL-12p70 (Fig. 2B); for TNF, a difference was 
seen after 7 days only (Fig. 1C and 2B); in contrast to data obtained with purified ManLAM 
and non-capped LAM (Geijtenbeek et al., 2003), BCG with capless LAM induced more IL-
10 than parent BCG (Fig. 2B). Also in vivo, after intravenous injection in C57/Bl6 mice (Fig. 
3), capless BCG was not attenuated as compared to parent strains, confirming earlier data 
following intranasal challenge in C57/Bl6 mice (Appelmelk et al., 2008) or intravenous 
injection in Balb/c mice (Festjens et al., 2011). Altogether these data show that studies with 
live capless LAM mutant bacteria yield data conflicting with those obtained with purified 
LAM. This could be due to several reasons. First, to show enhanced IL-10 (Geijtenbeek et 
al., 2003) or decreased IL-12 (Nigou et al., 2001; Pathak et al., 2005) production by purified 
ManLAM as compared to LAM without mannose caps, DC and macrophages were primed 
by the TLR4 ligand LPS; however, live mycobacteria are poor triggers of TLR4 signaling, A
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(Reiling et al., 2008) and hence, not surprisingly, live mycobacteria do not recapitulate the 
behavior of purified ManLAM. Second, we assume there is redundancy for the role of 
ManLAM. For example, binding of BCG to DC is dominated by DC-SIGN ligand 
interactions (Appelmelk et al., 2008; Geijtenbeek et al., 2003, Geurtsen et al., 2009) and 
when the cap, i.e. one of the ligands, is removed, binding to DC stays fully intact as a 
sufficient number of back-up ligands remains available e.g., PIMs (Driessen et al., 2009), 
lipomannan and glycoproteins (Pitarque et al., 2005).  We conclude that ligands other than 
the mannose cap determine binding to DC, and assume that a similar redundancy exists for 
other effects of ManLAM, such as the inhibition of phagolysosome fusion.   
A major goal of our studies was to evaluate the potency of capless BCG as a vaccine in 
a low dose M. tuberculosis aerosol challenge model. Based on the ability of ManLAM to 
induce immunosuppressive IL-10 (Geijtenbeek et al., 2003) one could expect that a capless 
BCG might be a more effective vaccine than parent BCG. Using a high dose murine M. 
tuberculosis challenge models (5x104 CFU intravenously or 2x105 CFU intratracheally), 
Festjens et al. (2011) showed that prior immunization with a capless BCG (105 CFU 
subcutaneously) indeed appeared to be more protective than parent BCG: mean survival time 
increased from 26.5 to 27.5 wk (intravenous challenge) and from 48 to 52 wk (intratracheal 
challenge); also after capless BCG immunization and i.v M. tuberculosis challenge, the 
weight loss was delayed as compared to immunization with parent BCG. However, the 
differences in protection between capless BCG and parent strain were small and not 
statistically significant (N. Festjens, pers. communication). We reasoned, based on early 
experience, that differences in immune protection could become more evident in a low dose 
challenge model (Appelmelk et al., 1986). The low dose aerosol M. tuberculosis infection A
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model is currently considered to be the golden standard to evaluate protective efficacy of 
tuberculosis vaccines. In the aerogenic model, infectious doses are as low as 10-25 CFU. The 
outcome of our studies (Fig. 4A) is that BCG and capless BCG hardly disseminate to the 
spleen or lung after intradermal injection, that (Figs. 4B and C) immune parameters following 
immunization were similar for both vaccines, and most importantly, the capless BCG had a 
protective efficacy identical to its parent strain (Fig. 4D).  
A second goal was to evaluate capless BCG in a particularly susceptible host, the 
guinea pig, an animal species which is also able to present the glycolipid LAM to T cells. 
Specialized CD1b lipid antigen presenting molecules are present in humans, but are lacking 
in mice. ManLAM has long been known to be presented by CD1b to antigen-specific T cells 
(Sieling et al., 1995), and hence in mice protection mediated by LAM-specific CD1b-
restricted T cells will not be evident. Guinea pigs in contrast express CD1b. In addition, 
unlike in mice, experimental tuberculosis in the guinea pigs causes caseating granulomas. 
Hence, as compared to mice the guinea pig model is seen as more representative of human 
disease and is an essential step in human tuberculosis vaccine development. To mimic natural 
disease, the aerogenic challenge route was again chosen. Fig. 5 shows that no differences in 
protection to M. tuberculosis infection were seen in this model following vaccination with the 
capless BCG or the parent strain.  
A final goal was to test the role in virulence of the mannose cap of M. tuberculosis, a 
species not tested hitherto. In vitro, we found no differences between wild type and capless 
M. tuberculosis with regards to replication rate in mouse macrophages, susceptibility to 
cytokine activated macrophages, and induction of TNF and nitrite secretion. To maximize the 
possibility to observe potential LAM-mediated immunomodulatory effects, we challenged A
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via the aerogenic route two immunologically contrasting mouse strains, i.e., Balb/c (a Th2-
skewed strain) and C57Bl/6 (a Th1-skewed strain) (see Fig. 7A and 7B, respectively). 
However, in both mouse strains capless M. tuberculosis and parent strain proliferated equally 
well. 
Altogether our data suggest that the dominant role attributed to the mannose cap of 
LAM, which was predominantly based on in vitro studies with purified ManLAM (Mishra et 
al., 2011) cannot be confirmed by in vivo studies in mice with isogenic pairs of mutants. The 
cap does not affect immunoprotection by BCG, nor does it affect virulence of pathogenic 
mycobacteria in mice. One explanation for this lack of effect is that the role of the cap might 
be redundant as discussed above. Still, the outcome of our studies is puzzling: we 
investigated, within the taxonomic tree of the genus Mycobacterium, which species expressed 
a mannose-capped LAM and we found it almost exclusively in slow growing species, many 
of which are pathogens; in fast growing, often environmental species, the cap was mostly 
lacking (Driessen and Appelmelk, unpublished). This suggests evolutionary pressure to 
preserve the cap. It cannot be excluded that the cap albeit not relevant in the biological assay 
systems tested so far with live mycobacteria, may still be important for example for 
transmission of M. tuberculosis from one person to another. As the DC-SIGN system in 
humans differs strongly from that of mice (Park et al., 2001), this aspect of tuberculosis is not 
accessible to animal experimentation; possibly, non-human primates mimic the human DC-
SIGN system more accurately. 
In short, together with two earlier studies, our novel data provide overwhelming 
evidence that the mannose cap of  lipoarabinomannan does not dominate the interaction of 
mycobacteria with the three experimental animal hosts (zebrafish, mice and guinea pigs) A
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tested. 
 
Experimental procedures: 
Mycobacterial strains and growth conditions: 
The BCG capA mutant, lacking the mannose cap of LAM, has been described and 
characterized before (Appelmelk et al., 2008). The capA mutant in M. tuberculosis H37Rv 
has not been described before and was constructed in a similar way via a two-step p1NIL-
pGOAL19 approach developed by Parish and Stoker (Parish et al., 2000), leading to a 
markerless deletion in the gene of interest (rv1635c). In fact, exactly the same plasmids were 
used to genetically modify BCG and M. tuberculosis: the DNA sequences of Rv1635c and its 
BCG homolog are 100% identical. Briefly, after the second step (sucrose selection) of the 
p1NIL-pGOAL procedure fourteen colonies were picked. The presence of this deletion was 
investigated by PCR. Phenotypically, the lack of mannose caps was investigated in 
immunoblot. In this colony dot blot, eleven of the colonies were non-reactive with the cap-
specific Mab 55.921A (Appelmelk et al., 2008) and three were reactive. In PCR those three 
yielded a rv1635c product, which was absent in the other eleven colonies. We concluded that 
of the fourteen colonies picked, three were revertants and eleven were (markerless) mutants 
lacking Rv1635c. These three mutants were investigated in SDS-PAGE-Immunoblot with 
monoclonal antibodies (MAbs) F30-5, 183-24, and 55.92.1A1, concanavalinA, and DC-
SIGN-Fc and further evidence was obtained they missed the cap (Supplementary Figure 3). 
Finally, one of the capless colonies was further investigated in capillary electrophoresis again 
providing evidence the cap is missing (Supplementary Figure 2). A complementant was also 
made: rv1635c was cloned into the shuttle vector pSMT3 and the construct electroporated in A
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the capA mutant of M. tuberculosis H37Rv. M. bovis BCG Copenhagen and mutant CapA 
were grown in liquid  Middlebrook 7H9 broth (Difco) supplemented with 0.05% Tween-80, 
until the log phase. The H37Rv M. tuberculosis wild type, capless mutant and complemented 
strain were grown in Proskauer-Beck medium (PB) containing 0.05% Tween 80 to mid–log 
phase. Cultures were aliquoted and frozen at –80°C until the day of use. 
Chemical analysis of the mannose caps: 
LAM from M. tuberculosis wild-type and M. tuberculosis capless mutant were 
analyzed for presence of the mannose cap by the capillary electrophoresis technique 
described earlier (Nigou et al, 2000). Briefly, purified LAM was partially degraded by 
controlled acid hydrolysis (0.1M HCl for 20 min. at 110°C), and the oligosaccharides 
liberated tagged with the fluorescent label 8-aminopyrene-1,3,6-trisulfonate (APTS). During 
CE, the labeled oligosaccharides are separated and peaks are detected by laser-induced 
fluorescence and migration times compared with the appropriate controls. 
Analysis of purified PIMs by Mass Spectrometry. 
Lipids were obtained by chloroform/methanol extraction of bacteria and subjected to 
MALDI-TOF MS analysis in the negative ion mode as previously described (Gilleron et al., 
2003). 
Laboratory mice: 
8 week-old female BALB/c and C57/B6 mice were purchased from Charles River 
(L'Arbresle, France) and housed under specific pathogen-free conditions in our facilities. 
Sterile chow and tap water ad libitum was given. All experiments were approved by and 
performed according to the guidelines of the animal ethical committee of IBMC. Five to 
seven animals were used per experimental group for each time-point. A
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BCG antigens for cell stimulation: 
Mycobacteria antigens were prepared as described elsewhere (Pais et al., 2000). BCG 
was grown until log phase, at 37°C, in Middlebrook 7H9 medium (Difco) supplemented with 
10% albumin/dextrose/catalase (ADC) and 0,05% Tween 80. The culture was centrifuged 
(10,000 x g, 40 minutes, 4°C) and the remaining pellet washed and re-suspended with 
phosphate-buffered saline (PBS), containing 0.1% Tween 80 (Sigma), 1 mM MgCl2 (Merck, 
Darmstadt, Germany) and 1 mM benzamidine (Sigma). The bacteria in suspension were 
disrupted through sonication with pulses of 1 min at maximum power, with the sample kept 
in ice during the whole procedure. The sonicate was centrifuged, to discard intact 
mycobacteria (30 min at 2,700 x g), and the supernatant was dialyzed against PBS (molecular 
weight cut-off of 12,000), followed by ultra-centrifugation for 2 h at 150,000 x g. The 
remaining pellet, containing the envelope proteins, was re-suspended in PBS, and the 
supernatant, enriched in cytosolic proteins, was precipitated with 80% ammonium sulfate and 
dialyzed against PBS. Aliquots were quantified and stored at -80°C until the day of use. 
Generation of bone marrow-derived macrophages (BMMØ) and dendritic cells 
(BMDC): 
Bone marrow cells were flushed from the femurs of mice with 5 ml of cold Hanks’ 
balanced salt solution (HBSS; Gibco, Paisley, United Kingdom) using a 26-gauge needle. For 
macrophage generation, the resulting cell suspension was centrifuged for 10min at 1200rpm, 
4ºC; resuspended in Dulbecco’s modified Eagle’s medium (DMEM; Gibco) supplemented 
with 10 mM HEPES (Sigma, St. Louis, MO), 1 mM sodium pyruvate (Gibco), 10 mM 
glutamine (Gibco), 10% heat-inactivated fetal bovine serum (Sigma), 10% L929 cell 
conditioned medium (LCCM, as a source of M-CSF) and cultured for a period of 4 h on cell A
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culture dishes (Nunc, Naperville, IL) in order to remove already differentiated cells. Non 
adherent cells were then collected with warm HBSS, counted, distributed in 24-well plates at 
a density of 5x105 cells/well and incubated in 1 ml of similar media at 37°C in a 5% CO2 
atmosphere. On day 4 after seeding, 100µL of LCCM was added and on day 7 the medium 
was renewed. Macrophages were infected at day 10. For dendritic cell differentiation, the cell 
suspension was cultured at a density of 106 cells/ml in RPMI 1640 containing GlutaMAX-I, 
supplemented with 5% v/v fetal calf serum (FCS), 50 mM β-mercaptoethanol and 10% GM-
CSF-containing culture supernatant from transformed J558 cells. Every 2 days, one-half of 
the media was removed and supplemented with complete medium with GM-CSF. On day 9, 
the non-adherent cells were cultured at 2 x 105 cells/ml in 96-well plate (100 µl/well), and 
infected at day 10. The purity of the population was determined by FACS analysis of specific 
surface markers and ranged from 85 to 95%. 
Macrophage infection: 
A bacterial suspension containing 5x106 CFU/mL was prepared and 200 µl was added 
to each well to obtain a multiplicity of infection (MOI) of 2 bacteria per macrophage. After 4 
h of incubation at 37°C in a 5% CO2 atmosphere, cells were washed with warm HBSS to 
remove the non-internalized bacteria, and re-incubated in DMEM with 10% LCCM. All 
treatments (100U IFNγ; 50U TNF) were applied from day zero until day 4. At different time 
points 100µl of supernatant was collected for subsequent cytokine measurements. For the 
CFUs assay, the infected cells were lysed with a 10% saponin solution, in sterilized water 
with 0,05% Tween 80, and serial dilutions of triplicate wells were performed. The number of 
viable bacteria was assessed by counting the colonies 3–4 weeks after plating on 7H11 Agar 
medium (Difco) supplemented with 10% oleic acid/ albumin/dextrose/catalase (OADC) and A
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incubated at 37°C.  
Dendritic cell infection: 
A bacterial suspension containing 5x106 CFU/mL was prepared and 100 µl was added 
to each well in order to obtain a multiplicity of infection (MOI) of 2 bacteria per DC. 
Supernatants were collected at different time points for IL-12p70, TNF and IL-10 cytokine 
measurements and the levels of expression of co-stimulatory molecules in cells were assessed 
by flow cytometry. 
Cytokine measurement: 
Cytokine detection in the supernatants was performed by ELISA.  For IFN-γ 
quantification, affinity-purified monoclonal antibodies (R4-6A2 as capture and biotinylated 
AN-18 as detecting antibody) were used, while commercial kits were used according to the 
manufacturer’s instructions for the detection of TNF, IL-10 (R&D Systems), IL-12p70, and 
IL-17A (Biolegend). 
Replication of M. bovis BCG in mice: 
Mice were infected intravenously through the lateral tail vein, with 5x104 CFU M. 
bovis BCG, wild type or mutant, in 200 µL of PBS. Bacterial loads in the organs of infected 
mice were evaluated at different time points post infection. Organs were homogenized in 
sterile water with 0.05% Tween 80 and ten-fold serial dilutions of organ homogenates were 
plated in duplicate onto Middlebrook 7H11 agar plates containing OADC. Plates where 
incubated at 37°C and colonies were counted 21 days later. Results are expressed as log CFU 
per organ. 
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Immunization and TB challenge: 
Balb/c mice were immunized by a single intradermal injection with 5x104 CFUs of M. 
bovis BCG, wild type or mutant. Two months later, mice were aerogenically infected with M. 
tuberculosis H37Rv using a Glass-col aerosol generation device chamber (Terre Haute, IN, 
USA). Briefly, mice were exposed for 30min to an aerosol produced by nebulizing 10 mL of 
PBS-Tween80 containing 106 CFU/ml that resulted in the implantation of 10-25 bacilli in the 
lung of each animal. Bacterial loads in the organs of infected mice were assessed by plating 
organ homogenates onto Middlebrook 7H11 agar plates, and counting the colonies formed 14 
to 21 days after incubation at 37ºC. Results are expressed as log CFU per organ. 
Guinea pig immunization and infection: 
Groups of 8 Dunkin–Hartley guinea pigs, weighing between 250 and 300 g (and free of 
infection), obtained from a commercial supplier (Harlan, UK), were used to evaluate the 
efficacy of capless BCG compared with BCG Danish 1331 (Statens Serum Institute, 
Copenhagen, Denmark), both delivered subcutaneously in a single dose at a concentration of 
5 x 104 CFU and a negative control (PBS vaccinated) group. Individual animals were 
identified using subcutaneously implanted microchips (PLEXX BV, The Netherlands). 
Guinea pig experimental work was conducted according to UK Home Office legislation for 
animal experimentation and was approved by the local ethics committee.  
Animals were infected with a low aerosol dose (10–50 CFU retained dose in the lung) 
of M. tuberculosis H37Rv (Williams et al., 2001) 12 weeks after vaccination. Aerosol 
challenge was performed using a fully contained Henderson apparatus as previously 
described (Chambers et al., 2000; Clark et al., 2011; Lever et al., 2000) in conjunction with 
the AeroMP (Biaera) control unit (Hartings et al., 2004). Fine particle aerosols of M. A
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tuberculosis H37Rv, with a mean diameter of 2 µm (diameter range, 0.5–7 µm) (Hartings et 
al., 2004) were generated using a Collison nebulizer and delivered directly to the animal 
snout. The aerosol was generated from a water suspension containing 5 x 106 CFU/ml in 
order to obtain an estimated retained, inhaled dose of approximately 10–50 CFU/lung. The 
Henderson apparatus allows controlled delivery of aerosols to the animals and the 
reproducibility of the system and relationship between inhaled CFU and the concentration of 
organisms in the nebulizer has been described previously (Chambers et al., 2000; Clark et al., 
2011). The challenge system is controlled by an AeroMP: the aerosol management platform 
controls, monitors, and records all relevant parameters during an aerosol procedure including 
air flow rate, temperature and relative humidity (Hartings et al., 2004). At 4 weeks post-
challenge, guinea pigs were killed humanely by intraperitoneal injection of pentabarbitone 
(Euthatal). Post-mortem, tissues were aseptically removed for bacteriology analysis. Tissues 
were homogenized in 5 ml of sterile distilled water using a rotating blade macerator system 
(Ystral, UK). Viable counts were performed on the macerate by preparing serial dilutions in 
sterile deionized water and plating 100 µl aliquots onto Middlebrook 7H11 + OADC agar 
(BioMerieux, UK). Plates were incubated at 37 °C for 3 weeks before counting the number of 
M. tuberculosis colonies (CFU). 
Cell preparation and in vitro stimulation: 
Spleens were gently disrupted with the help of a cell glass homogenizer. The resulting 
cell suspension was passed through a 70 µm nylon cell strainer, in order to remove large 
pieces and debris. Lung cell suspensions were obtained as follows: thoracic cavities were 
opened, and sterile PBS was gently injected into the right heart ventricles to perfuse lungs. 
Lungs were excised, sectioned, and incubated with digestion media (DMEM supplemented A
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with Collagenase IX (0.7 mg/ml; Sigma) for 30 min at 37°C. The final cell suspension was 
obtained by passing the digested lung tissue through a 70 µm nylon cell strainer. In all cell 
suspensions the red blood cells were lysed with a hemolytic solution (155 mM NH4Cl, 10 
mM KHCO3 (pH 7.2)) during 5 min at room temperature. Cells were then distributed into 96-
well plates (2.5 x 105 cells/well) and incubated in triplicate with different stimuli: DMEM 
culture medium and 4 µg/ml of ConA (Sigma-Aldrich) as negative and positive controls, 
respectively, and depending on the experiment, 4µg/ml of BCG extract or 1.25x105 of live M. 
tuberculosis H37Rv bacilli. After 72h of incubation at 37°C in a 5% CO2 atmosphere, the 
supernatants were collected for cytokine measurement. For intracellular staining, 1 x 106 
cells/ml were incubated for 4 h at 37°C in the presence of PMA (Sigma-Aldrich) plus 
ionomycin (Calbiochem) at a final concentration of 25 µg/ml each, followed by an incubation 
of 2 h in the presence of 0.01 mg/ml brefeldin A (Sigma-Aldrich). Then, cells were fixed, 
permeabilized and stained with IFNγ-specific antibodies. 
Flow cytometry: 
Cells were labeled with specific antibodies for CD3 (clone 145-2C11), CD4 (clone 
RM4-5), CD8 (clone 53-6.7), CD11b (clone M1/70), CD19 (clone 6D5), DX5 (clone HMα2), 
CD25 (clone PC61), CD86 (clone GL-1), CD40 (clone 5C3), MHC-II (clone M5/114.15.2) 
from BioLegend, San Diego, CA) and FOXP3 (e-bioscience). Cell populations were acquired 
in a FACS Calibur instrument equipped with CellQuest software. Data were analyzed using 
FlowJo software (Tree Star, Ashland, OR).  
Statistical analysis: 
Data were analyzed by using Student’s t test. Statistical analyses of guinea pig data 
were performed using Minitab (version 13.32). The CFU data were analyzed by non-A
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parametric Mann–Whitney test comparisons to compare median values of the vaccine group 
with either the saline or BCG control groups. 
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Figure legends 
Figure 1: In vitro interaction of BCG with macrophages. A- Growth of wild type (WT) or 
capless (CapA) mutant BCG in bone marrow derived macrophages (BMDM) from Balb/c 
mice.  B- Survival of WT and capless (CapA) mutant BCG in untreated BMDM or BMDM 
treated with 50U TNF, 100U IFNγ or both (results expressed as “log CFU increase", that 
corresponds to the difference of growth, in log CFU, between day 7 and day 0). C- Secretion 
of TNF into the culture medium by BMDM infected with the BCG strains. D- Release of 
nitrite into the culture supernatants by BMDM infected with BCG and treated with IFNγ. 
Data represent the mean ± 1SD of a representative experiment out of a total of 3 experiments. 
Statistically significant differences are labeled with an asterisk. 
 
Figure 2: In vitro interaction of BCG with dendritic cells. A- Expression of co-
stimulatory molecules in bone marrow-derived dendritic cells infected with WT or capless 
(CapA) mutant BCG as evaluated by flow cytometry. B- Secretion of IL-12p70, IL-10 and 
TNF by dendritic cells infected with WT or capless (CapA) mutant BCG. Data represent the 
mean ± 1SD of a representative experiment out of a total of 3 experiments. Statistically 
significant differences are labeled with an asterisk. 
 
Figure 3: Capless M. bovis BCG replicates similarly and induces identical immune 
responses as compared to the WT strain. A- Proliferation of WT or capless (CapA) mutant 
BCG in the liver and spleen of BALB/c mice intravenously infected with 5x104 CFUs. B- 
Secretion of IFNγ, TNF and IL-10 into the culture supernatants by splenocytes from the 
infected animals following in vitro re-stimulation with 4µg/ml of M. bovis BCG extract for A
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72h. A total of 5 to 7 mice per time point were used, and all results are representative of at 
least two independent experiment. 
 
Figure 4: Capless and wild type M. bovis BCG induce the same level of protection to a 
M. tuberculosis challenge in the low dose aerosol mouse model. A- Dissemination of WT 
and capless (CapA) mutant BCG, after subcutaneous immunization with 5x104 CFU. The 
number of CFU in the spleen and lung were assessed 70 days after immunization. B- 
Quantification of cytokine responses in the lungs of vaccinated mice. 70 days post 
immunization, lung cell suspensions were re-stimulated in vitro with 4µg/ml of BCG extract 
for 72h and cytokines measured in the supernatants. C- Number of CD4+IFNγ+ cells in the 
lungs of vaccinated mice at day 70 post immunization, determined by intracellular cytokine 
staining of lung cell suspensions re-stimulated in vitro with PMA and Ionomycin. D- 
Protective efficacy of WT versus capless (CapA) mutant BCG in a M. tuberculosis challenge. 
Balb/c mice were immunized with 5x104 CFU of parental or mutant CapA BCG. Two 
months later, mice were aerogenically infected with approximately 100 CFU of M. 
tuberculosis H37Rv. Mice were sacrificed at days 1, 30, and 90 post-infection and the 
number of bacteria in lungs and spleens determined. In all experiments a total of 5 to 7 mice 
per time point were used and all results are representative of at least two independent 
experiments. Significant values are labeled by an asterisk.  
 
Figure 5: Capless and wild type M. bovis BCG induce the same level of protection against 
a M. tuberculosis challenge in the low dose aerosol guinea pig model. Bacterial load of 
viable M. tuberculosis in spleen and lung of guinea pigs was determined. Adult guinea pigs A
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were infected, sacrificed (8 per group) after 4 weeks and lung and spleen homogenates were 
plated for enumeration of bacilli (total CFU). Horizontal bars indicate medians after log 
transformation; error bars indicate range and p values represent statistical comparisons (Mann-
Whitney test) between BCG WT(closed circles) and PBS (closed squares) control groups and 
capless BCG (open circles). 
 
Figure 6: In vitro interaction of M. tuberculosis with macrophages. A- Growth of wild 
type (WT) or capless (CapA) mutant M. tuberculosis in bone marrow derived macrophages 
(BMDM) from Balb/c mice.  B- Survival of WT and capless (CapA) mutant M. tuberculosis 
in untreated BMDM or BMDM treated with 50U TNF, 100U IFNγ or both (results expressed 
as “log CFU increase", that corresponds to the difference of growth, in log CFU, between day 
7 and day 0). C- Secretion of TNF into the culture medium by BMDM infected with the M. 
tuberculosis strains. D- Release of nitrite into the culture supernatants by BMDM infected 
with M. tuberculosis and treated with IFNγ. Data represent the mean ± 1SD of a 
representative experiment out of a total of 3 experiments. No statistically significant 
differences were found. 
 
Figure 7: Capless and wild type M. tuberculosis have the same virulence. A- Proliferation 
of WT, capless (CapA) mutant and Complementant strains of M. tuberculosis in the lung and 
spleen of Balb/c mice following an aerogenic infection leading to the implantation of 10 to 25 
bacilli in the lung of each animal. B- Secretion of IFNγ, TNF and IL-17 into the culture 
supernatants by lung leukocytes from Balb/c mice infected for 60 days and following in vitro 
re-stimulation with live M. tuberculosis bacilli for 72h. C- Proliferation of M. tuberculosis A
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WT or capless (CapA) mutant in C57BL/6 mice following an aerogenic infection. Mice were 
sacrificed at days 1 and 120 post-infection and the bacterial loads in the lung and spleen 
determined. Results are expressed as "log CFU increase", that corresponds to the difference 
of growth, in log CFU, between day 1 and day 120. A total of 5 to 7 mice per time point were 
used. 
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Table 1: M. bovis BCG CapA mutant induces identical immune responses as compared to the wild type strain.  
Balb/c mice were intravenously infected with 5x104 CFUs of M. bovis BCG WT or CapA mutant. The animals were sacrificed at various time 
points and spleen cells were labeled with specific antibodies for flow cytometric analysis of the splenic cell population. A total of 5 to 7 mice per 
time point were used, and all results are representative of at least two independent experiments 
 
 
Average cells x 10 7 ± SD 
 
 
CD4+ CD8+ CD4+Foxp3+ CD19+ CD3+DX5+ DX5+ CD11b+ 
Days WT CapA WT CapA WT CapA WT CapA WT CapA WT CapA WT CapA 
10 1.2±0.2 1.2±0.2 0.6±0.1 0.6±0.1 0.2±0.02 0.2±0.02 2.4±0.6 2.1±0.9 0.1±0.01 0.1±0.02 0.2±0.08 0.2±0.07 0.3±0.1 0.3± 
0.1 
20 1.5±0.3 1.5±0.4 0.7±0.1 0.6±0.1 0.2±0.03 0.2±0.05 3.6±0.7 3.6±0.9 0.1±0.02 0.1±0.03 0.3±0.08 0.3±0.09 0.6±0.2 0.6± 
0.2 
30 1.8±0.4 1.5±0.1 0.6±0.2 0.5±0.1 0.3±0.06 0.2±0.03 3.9±0.6 3.3±0.7 0.1±0.03 0.1±0.02 0.4±0.04 0.4±0.07 0.7±0.2 0.6± 
0.1 
60 1.6±0.2 1.4±0.3 0.6±0.1 0.5±0.1 0.2±0.03 0.2±0.03 4.1±0.6 3.4±0.5 0.1±0.04 0.1±0.03 0.3±0.07 0.3±0.03 0.8±0.1 0.6± 
0.1 
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